drugset
drugset / Trial / NCT05023928

Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer

NCT05023928 ↗

Phase 1 Completed 25 enrolled Sichuan University
NaSingle-groupOpen-labelTreatment

Summary

The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of esophageal cancer.

Timeline

Start
2021-09-01
Primary completion
2023-10-01
Completion
2024-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tumor antigen-sensitized DC vaccine Vaccine — Subcutaneous

Indications

carcinoma esophageal cancer